# Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

> **NCT03501550** · PHASE2 · COMPLETED · sponsor: **Cocrystal Pharma, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** CDI-31244
- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT03501550
- **Lead sponsor:** Cocrystal Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-26
- **Primary completion:** 2019-01-08
- **Final completion:** 2019-06-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03501550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03501550, "Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03501550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*